Weibo Luo
- Cancer Research top 0.2%
- Cancer, Hypoxia, and Metabolism 35
- Protease and Inhibitor Mechanisms 5
- Immunology top 2%
- Molecular Biology top 1%
- Mitochondrial Function and Pathology 12
- RNA modifications and cancer 10
- Epigenetics and DNA Methylation 9
- ATP Synthase and ATPases Research 4
- Oncology top 2%
- Biochemistry top 2%
-
- Blood Coagulation and Thrombosis Mechanisms 9
-
- Adipose Tissue and Metabolism 4
Weibo Luo
83 papers receiving 7.3k citations
Hit Papers
Peers
Comparison fields: 5 of 130
- Cancer Research 3.3k
- Immunology 1.5k
- Molecular Biology 4.2k
- Oncology 1.1k
- Biochemistry 249
Countries citing papers authored by Weibo Luo
This map shows the geographic impact of Weibo Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weibo Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weibo Luo more than expected).
Fields of papers citing papers by Weibo Luo
This network shows the impact of papers produced by Weibo Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weibo Luo. The network helps show where Weibo Luo may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Weibo Luo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 4 | |
| 2 | 2025 | 3 | |
| 3 | 2024 | 2 | |
| 4 | 2023 | 4 | |
| 5 | 2022 | 25 | |
| 6 | 2022 | 11 | |
| 7 | 2022 | 36 | |
| 8 | 2021 | 7 | |
| 9 | 2021 | 14 | |
| 10 | 2021 | 66 | |
| 11 | 2021 | 31 | |
| 12 | 2020 | 45 | |
| 13 | 2020 | 147 | |
| 14 | 2020 | 14 | |
| 15 | 2020 | 15 | |
| 16 | 2018 | 12 | |
| 17 | 2014 | 48 | |
| 18 | 2013 | 3 | |
| 19 | Emerging roles of PKM2 in cell metabolism and cancer progressionbreakdown → | 2012 | 290 |
| 20 | 2012 | 214 |
About Weibo Luo
Weibo Luo is a scholar working on Cancer Research, Aging and Hematology, having authored 85 papers that have together received 7.4k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (35 papers), Mitochondrial Function and Pathology (12 papers), RNA modifications and cancer (10 papers), Blood Coagulation and Thrombosis Mechanisms (9 papers), Epigenetics and DNA Methylation (9 papers), Protease and Inhibitor Mechanisms (5 papers), ATP Synthase and ATPases Research (4 papers) and Adipose Tissue and Metabolism (4 papers). The work is most often cited by research in Cancer Research (3.3k citations), Immunology (1.5k citations) and Molecular Biology (4.2k citations). Weibo Luo has collaborated with scholars based in United States, China and Germany. Frequent co-authors include Gregg L. Semenza, Yingfei Wang, Hongxia Hu, Jun Zhong, Akhilesh Pandey, Georg Reiser, Robert N. Cole, Robert N. O’Meally, Daniele M. Gilkes and Matthew Knabel. Their work appears in journals such as Journal of Clinical Investigation, Oncotarget, Journal of Neurochemistry, Cellular and Molecular Life Sciences and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.